NasdaqGM:LGNDPharmaceuticals
Is Ligand Pharmaceuticals’ (LGND) $400 Million Convertible Bond Marking a Shift in Capital Flexibility Strategy?
Ligand Pharmaceuticals recently completed a US$400 million convertible bond offering with 0.75% senior unsecured notes due 2030 and amended its credit agreement to permit certain cash settlement payments on these notes, following positive Q2 earnings and a raised annual revenue outlook for 2025.
This sequence of financial actions signals increased financial flexibility that could support the company’s continued expansion of its royalty portfolio and future partnership opportunities.
We’ll...